ARCHIVES

New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years

This article is from The Cancer Letter archive.

Vol. 35 No. 10 | October 26, 2012

Download PDF Visit The Full Archive

Related Articles

American Home Products Changes Name To Wyeth.

March 1, 2002

Tamoxfin Trial accrues 6,000, Problems with Minority accrual Remain

April 2, 1993

New Grant Concepts Totaling $3 million a Year Approved, With New Contract, Two Recompetitions

July 10, 1987

DCT Board Approves Concepts For New RFA, New And Recompeting Contracts

June 18, 1982

In Brief: Robert Bast Succeeds Singleton As Director Of Duke Cancer Center; Robert Bell Deputy

August 14, 1987

Call to Shift Two-Thirds Of Funds a “Rubber Number,” Bailar Says

June 6, 1997